Contraindicated in patients with serious hypersensitivity to fremanezumab or to any of the excipients.
Fremanezumab-Vfrm is biosimilar to Fremanezumab.
- TRADE NAMES: Ajovy (Teva); TEV-48125 (Teva)
- INDICATIONS: Migraine in adults
- CLASS: Calcitonin gene-related peptide (CGRP) receptor antagonist, Monoclonal antibody
- HALF-LIFE: ~31 days
- FDA APPROVAL DATE: 09/14/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: There are no adequate data on the developmental risk associated with the use of fremanexumab in pregnant women. The long half life of fremanezumab should be a consideration for women who are pregnant or plan to become pregnant while using fremanezumab.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fremanezumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/23/2024
